The earnings call highlights significant achievements such as the strong launch of O2VERE, robust financial performance, and strategic advancements in pipeline and market expansion. However, challenges remain with operating losses and seasonality impacts. Overall, the positive developments and financial strength present an optimistic outlook for the company.

Company Guidance

During the first quarter of 2025, Verona Pharma plc achieved significant milestones, particularly with the US launch of O2VERE for COPD. The company reported $71.3 million in net product sales for O2VERE, nearly doubling from the previous quarter, and total net revenue of $76.3 million, including a $5 million clinical milestone from Nuance Pharma. Prescriptions increased to 25,000, with new patient starts up by over 25% and refills accounting for 60% of expenses. The prescriber base expanded by 50% to approximately 5,300, with 60% identified as tier one healthcare providers. Verona also strengthened its financial position, maintaining $401.4 million in cash and equivalents and amending its debt facility to $450 million. Additionally, a new Orange Book patent extending to 2044 was granted, enhancing O2VERE's intellectual property portfolio.

Successful Launch of O2VERE

O2VERE's launch for COPD treatment has doubled sales from Q4 2024 to Q1 2025, reaching $71.3 million with 25,000 prescriptions filled and a 50% increase in prescriber base.

Financial Performance Exceeds Expectations

For the first time, quarterly revenue exceeded operating expenses excluding noncash charges. Q1 2025 net revenue was $76.3 million, with an adjusted net income of $20.5 million.

Strong Financial Position

Cash and equivalents increased to $401.4 million by March 2025. Strategic financing arrangement with Oaktree and OMERS was amended, increasing the debt facility to $450 million on more favorable terms.

Expansion of O2VERE's Market

O2VERE was approved in Macau for COPD treatment, marking its first regulatory approval outside the US. Potential EU and UK marketing authorization applications are in progress.

Pipeline Advancements

Initiating a Phase 2b trial for a fixed-dose combination of ensifentrine and glycopyrrolate. Continued enrollment in a Phase 2 trial for nebulized ensifentrine in non-CF bronchiectasis.

New Patent for O2VERE

A new Orange Book listed patent was granted with an expiration date in 2044, enhancing the intellectual property protection for O2VERE.

Verona Pharma (VRNA) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

VRNA Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 11, 2025	2025 (Q3)	- / -	-0.07	―	―	―
Jul 31, 2025	2025 (Q2)	0.06 / 0.13	-0.11	220.91% (+0.24)	―	―
Apr 29, 2025	2025 (Q1)	-0.08 / -0.02	-0.04	50.00% (+0.02)	―
Feb 27, 2025	2024 (Q4)	-0.03 / -0.05	-0.02	-150.00% (-0.03)	―
Nov 04, 2024	2024 (Q3)	-0.07 / -0.07	-0.02	-250.00% (-0.05)	―
Aug 08, 2024	2024 (Q2)	-0.04 / -0.11	-0.01	-1000.00% (-0.10)	―
May 09, 2024	2024 (Q1)	-0.03 / -0.04	-0.03	-33.33% (-0.01)	―
Feb 29, 2024	2023 (Q4)	-0.03 / -0.02	-0.02	0.00% (0.00)	―
Nov 02, 2023	2023 (Q3)	-0.03 / -0.02	-0.03	33.33% (<+0.01)	―
Aug 03, 2023	2023 (Q2)	-0.03 / -0.01	-0.04	75.00% (+0.03)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

VRNA Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 31, 2025	$105.14	$105.09	-0.05%
Apr 29, 2025	$68.83	$73.22	+6.38%
Feb 27, 2025	$63.52	$67.12	+5.67%
Nov 04, 2024	$34.98	$38.15	+9.06%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Verona Pharma Plc (VRNA) report earnings?

Verona Pharma Plc (VRNA) is schdueled to report earning on Nov 11, 2025, TBA (Confirmed).

What is Verona Pharma Plc (VRNA) earnings time?

Verona Pharma Plc (VRNA) earnings time is at Nov 11, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is VRNA EPS forecast?

Currently, no data Available

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing